Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer
2006
Cancer Prevention: From 1727 to Milestones of the Past 100 Years
2009
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
2009 Standout
Breast cancer prognosis by combinatorial analysis of gene expression data
2006
Attenuated Bacteria as Effectors in Cancer Immunotherapy
2008
Inflammation and cancer
2002 StandoutNature
Systemic and Vascular Inflammation in Patients With Moderate to Severe Psoriasis as Measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography –Computed Tomography (FDG-PET/CT)
2011
Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral meningitis
1999
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial
2005
Molecular mechanism and function of CD40/CD40L engagement in the immune system
2009
TLR based therapeutics
2011
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
2016
Cancer immunotherapy via dendritic cells
2012 Standout
Cardiovascular aspects of psoriasis: an updated review
2013
Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study
2010
Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth
2008
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
2011
Engineering the perfect (bacterial) cancer therapy
2010 Standout
Cytokine regulation of cellular adhesion molecule expression in inflammation
1999
BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa
2003
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Inflammation and Colon Cancer
2010 Standout
Psoriasis
2015 Standout
T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept
2014
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Immunotherapeutic Strategies for High-Risk Bladder Cancer
2007 StandoutNobel
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Prospects for CD40-directed experimental therapy of human cancer
2002
Bladder cancer
2016 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
2009 Standout
R‐form LPS, the master key to the activation ofTLR4/MD‐2‐positive cells
2006 StandoutNobel
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis
2008
Nutrition and the Immune System
1996
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
2015
IL-18-producing Salmonella inhibit tumor growth
2008
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Tumour necrosis factor and cancer
2009
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
2010 StandoutNobel
ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome
2007 Standout
Defining trained immunity and its role in health and disease
2020 Standout
Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain ofSalmonella typhimurium
2000
The mechanism of action of BCG therapy for bladder cancer—a current perspective
2014
A Case of Pott’s Disease with Epidural Abscess and Probable Cerebral Tuberculoma following Bacillus Calmette‐Guérin Therapy for Superficial Bladder Cancer
2010
Role of innate cytokines in mycobacterial infection
2011
PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata
2007
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Toll-Like Receptors
2003 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
2009 Standout
Microorganisms and Cancer: Quest for a Therapy
2003
Antioxidant Properties of Various Solvent Extracts of Total Phenolic Constituents from Three Different Agroclimatic Origins of Drumstick Tree (Moringa oleifera Lam.) Leaves
2003 Standout
Follicular Helper CD4 T Cells (TFH)
2011 Standout
Psoriasis Pathogenesis and Treatment
2019 Standout
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
Echinococcosis: Advances in the 21st Century
2019 Standout
Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides
2002 Standout
Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
2003 StandoutNobel
Therapeutic targeting of trained immunity
2019
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
CpG Motifs in Bacterial DNA and Their Immune Effects
2002 Standout
2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa
2015 Standout
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer.
2007
Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine.
1999
AttenuatedSalmonellaengineered to produce human cytokine LIGHT inhibit tumor growth
2007
CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma
2013 StandoutNobel
Neutrophil Granulocytes Are Required for EffectiveBacillus Calmette-GuerinImmunotherapy of Bladder Cancer and Orchestrate Local Immune Responses
2006
The Immune Response in Tuberculosis
2013 Standout
URINARY INTERLEUKIN-8 AND 18 PREDICT THE RESPONSE OF SUPERFICIAL BLADDER CANCER TO INTRAVESICAL THERAPY WITH BACILLUS CALMETTE-GUERIN
2000
Association between Echinococcus granulosus infection and cancer risk – a pilot study in Cyprus
2016
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
2007
Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo
2000
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
B cell–intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice
2021 StandoutNobel
Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti‐inflammatory drugs: a D anish real‐world cohort study
2012
BCG immunotherapy for superficial bladder cancer
2001
Phytochemicals: nutraceuticals and human health
2000 Standout
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
2003
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes
2012 Standout
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Maturation of Human Dendritic Cells by Cell Wall Skeleton ofMycobacterium bovisBacillus Calmette-Guerin: Involvement of Toll-Like Receptors
2000
Works of A.B. Alexandroff being referenced
Mechanisms of Action of Intravesical Bacille Calmette-Guérin: Local Immune Mechanisms
2000
More than skin deep: atherosclerosis as a systemic manifestation of psoriasis
2009
Soluble urinary CD14 after intravesical bacille Calmette‐Guérin immunotherapy for carcinoma in situ
1997
Autocrine regulation of ICAM-1 expression on bladder cancer cell lines: evidence for the role of IL-1α
1994
BCG immunotherapy of bladder cancer: 20 years on
1999
Role for CD40âCD40 ligand interactions in the immune response to solid tumours
2000
Interleukin-6 Production by Bladder Tumors is Upregulated by BCG Immunotherapy
1995
Control of leucocyte function-associated antigen-1-dependent cellular conjugation by divalent cations.
1994
Production of IL-5, a classical T(H)2 cytokine, following bacillus Calmette guerin immunotherapy of bladder cancer
1996
Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.
1998
Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.
1994
Recent advances in bacillus Calmette–Guerin immunotherapy in bladder cancer
2010
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) immunotherapy
1995
PROGNOSIS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR SUPERFICIAL BLADDER CANCER BY IMMUNOLOGICAL URINARY MEASUREMENTS: STATISTICALLY WEIGHTED SYNDROMES ANALYSIS
1998